Actelion sticks to outlook for 2012
Home page > News

Actelion sticks to outlook for 2012

www.reuters.com   | 18.10.2012.

ZURICH (Reuters) - Europe's largest biotechnology company Actelion stuck to its 2012 guidance for core earnings growth in the mid-single digit range as nine month sales of its most important drug slid 4 percent.
br />

Sales of its pulmonary arterial hypertension (PAH) blockbuster Tracleer fell 4 percent to 1.13 billion Swiss francs ($1.22 billion) in the first nine-months of 2012.

The company received a much needed boost to its pipeline in April from impressive data for its new heart and lung drug macitentan, reassuring investors its business won't trickle away once Tracleer goes off patent in 2015.

($1 = 0.9229 Swiss francs)

(Reporting by Caroline Copley)


Comments (0) Add Your comment Add news < Previous news Next news >






  Add your news >>>